Yang SH - Search Results

1

The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan.

Yang SH, Chiang NJ, Chiu SC, Chou WC, Bai LY, Li CP, Su YY, Chiu TJ, Chuang SC, Peng CM, Chan DC, Chen JS, Yen CJ, Chen YY, Chiu CF, Chen LT, Shan YS. Yang SH, et al. Am J Cancer Res. 2022 Apr 15;12(4):1884-1898. eCollection 2022. Am J Cancer Res. 2022. PMID: 35530292 Free PMC article.

2

Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan.

Chang MC, Wu CH, Yang SH, Liang PC, Chen BB, Jan IS, Chang YT, Jeng YM. Chang MC, et al. Among authors: yang sh. Am J Cancer Res. 2017 Feb 1;7(2):357-369. eCollection 2017. Am J Cancer Res. 2017. PMID: 28337383 Free PMC article.

3

A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.

Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS, Shan YS, Chen LT. Chiang NJ, et al. Among authors: yang sh. Eur J Cancer. 2020 Jan;124:123-130. doi: 10.1016/j.ejca.2019.10.023. Epub 2019 Nov 22. Eur J Cancer. 2020. PMID: 31765987 Clinical Trial.

4

Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study.

Chiang NJ, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS, Shan YS, Chen LT. Chiang NJ, et al. Among authors: yang sh. Liver Int. 2020 Oct;40(10):2535-2543. doi: 10.1111/liv.14538. Epub 2020 Jun 9. Liver Int. 2020. PMID: 32463975 Free PMC article. Clinical Trial.

5

Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling.

Kuo SH, Yang SH, Wei MF, Lee HW, Tien YW, Cheng AL, Yeh KH. Kuo SH, et al. Among authors: yang sh. Cancer Cell Int. 2021 Aug 19;21(1):436. doi: 10.1186/s12935-021-02143-z. Cancer Cell Int. 2021. PMID: 34412631 Free PMC article.

6

Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma.

Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH. Yang SH, et al. Oncoimmunology. 2021 Sep 27;10(1):1973710. doi: 10.1080/2162402X.2021.1973710. eCollection 2021. Oncoimmunology. 2021. PMID: 34595057 Free PMC article.

7

Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study.

Chiu TJ, Su YY, Yang SH, Li CP, Bai LY, Chiang NJ, Chuang SC, Shan YS, Chan DC, Chen LT, Yen CJ, Peng CM, Chen YY, Chen JS, Chou WC. Chiu TJ, et al. Among authors: yang sh. Ther Adv Med Oncol. 2021 Nov 20;13:17588359211058255. doi: 10.1177/17588359211058255. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34819998 Free PMC article.

8

A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study.

Su YY, Chiu YF, Li CP, Yang SH, Lin J, Lin SJ, Chang PY, Chiang NJ, Shan YS, Ch'ang HJ, Chen LT. Su YY, et al. Among authors: yang sh. Br J Cancer. 2022 Apr;126(7):1018-1026. doi: 10.1038/s41416-021-01649-7. Epub 2021 Dec 17. Br J Cancer. 2022. PMID: 34921230 Free PMC article. Clinical Trial.

9

Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.

Chiu TJ, Yang SH, Chiu SC, Hsueh SW, Chiang NJ, Li CP, Bai LY, Cheng FM, Chuang SC, Shan YS, Chan DC, Chen LT, Yen CJ, Peng CM, Su YY, Chen YY, Chen JS, Chou WC. Chiu TJ, et al. Among authors: yang sh. J Hepatobiliary Pancreat Sci. 2022 Jun;29(6):670-681. doi: 10.1002/jhbp.1128. Epub 2022 Mar 2. J Hepatobiliary Pancreat Sci. 2022. PMID: 35182031

10

Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma.

Yang SH, Lee JC, Chen BB, Kuo SH, Hsu C, Bai LY. Yang SH, et al. Front Immunol. 2022 Apr 28;13:870406. doi: 10.3389/fimmu.2022.870406. eCollection 2022. Front Immunol. 2022. PMID: 35572526 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,768 results

Search Page